News | April 06, 2022
ENTOD Pharma bullish on Macushield sales
Macushield tablets assist with age-related macular degeneration, diabetic retinopathy and improves overall vision
Macushield tablets assist with age-related macular degeneration, diabetic retinopathy and improves overall vision
Intas has developed a biosimilar of Lucentis, which is currently under Phase III global trial for submission in major countries including EMA & the US
As part of this partnership, Huma and AstraZeneca will launch Software as a Medical Device (SaMD) companion apps targeted at several therapeutic areas and will partner to help accelerate the adoption of decentralized clinical trials
OxemiaTM (Desidustat) is an oral tablet formulation that is the first-in-India alternative to injectable erythropoietin-stimulating agents (ESAs)
Vabysmo is the only injectable eye medicine approved simultaneously in the US for wet AMD and DME, with flexible dosing regimens based on patient need
Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma
The Academy endeavours to reach all levels of the society in creating programs that are accessible to one and all with training for Health Volunteers, Asha, Angavadi, school-teachers and students as part of life-skill development
Acquisition will add GT005 to the Novartis portfolio, an investigational, one-time gene therapy currently in Phase 2 for the treatment of people living with Geographic atrophy
The U.S. FDA advisory committee voted 13-10 in favour of the oral antiviral medicine
A Sanofi R&D executive will join the Gyroscope Clinical Advisory Board to advise on matters related to the development of GT005 for geographic atrophy (GA).
Subscribe To Our Newsletter & Stay Updated
